MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection

By Gentile Ivan   Buonomo Antonio Riccardo   Borgia Federico   Zappulo Emanuela   Castaldo Giuseppe   Borgia Guglielmo  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 5, 2014-05 ,pp. : 719-728

Informa Healthcare

Access to resources Recommend Favorite

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

By Isaacs John T  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 10, 2010-10 ,pp. : 1235-1243

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor

By Bannwarth Bernard   Berenbaum Francis  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 4, 2005-04 ,pp. : 521-533

Informa Healthcare

Access to resources Recommend Favorite

A review of the second-generation antihistamine ebastine for the treatment of allergic disorders

By Van Cauwenberge Paul   De Belder Tine   Sys Lien  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 8, 2004-08 ,pp. : 1807-1813

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacokinetics of second generation antisense oligonucleotides

By Yu Rosie Z   Grundy John S   Geary Richard S  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 2, 2013-02 ,pp. : 169-182

Informa Healthcare

Access to resources Recommend Favorite